Diclofenac inhibits tumor growth in a murine model of pancreatic cancer by modulation of VEGF levels and arginase activity

PLoS ONE

Volumn 5, Issue 9, 2010, Pages 1-10

  Mayorek, Nina ^a   Naftali Shani, Nili ^a   Grunewald, Myriam ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE; ARGINASE 1; DICLOFENAC; NITRIC OXIDE; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DEPLETION; DOWN REGULATION; ENZYME ACTIVITY; EX VIVO STUDY; FEMALE; IN VIVO STUDY; LEUKOCYTE; MALE; MEDIATOR; MOUSE; NONHUMAN; PANCREAS CANCER; PERITONEAL CAVITY; PERITONEUM MACROPHAGE; PROTEIN CONTENT; RAT; STROMA CELL; TUMOR VASCULARIZATION; ANIMAL; CELL PROLIFERATION; DISEASE MODEL; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PANCREAS TUMOR; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT;

MURINAE; MUS;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARGINASE; CELL PROLIFERATION; DICLOFENAC; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FEMALE; HUMANS; MALE; MICE; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; RATS; RATS, SPRAGUE-DAWLEY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77958606868     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012715     Document Type: Article

References (41)

1. Le Bitoux MA, Stamenkovic I (2008) Tumor-host interactions: the role of inflammation. Histochem Cell Biol 130: 1079-1090.
2. Gupta RA, Dubois RN (2001) Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 1: 11-21.
3. Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, et al. (2009) The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 30: 377-386.
4. Michaud DS (2004) Epidemiology of pancreatic cancer. Minerva Chir 59: 99-111.
5. Farrow B, Albo D, Berger DH (2008) The role of the tumor microenvironment in the progression of pancreatic cancer. J Surg Res 149: 319-328.
6. Colby JK, Klein RD, McArthur MJ, Conti CJ, Kiguchi K, et al. (2008) Progressive metaplastic and dysplastic changes in mouse pancreas induced by cyclooxygenase-2 overexpression. Neoplasia 10: 782-796.
7. Funahashi H, Satake M, Dawson D, Huynh NA, Reber HA, et al. (2007) Delayed progression of pancreatic intraepithelial neoplasia in a conditional Kras(G12D) mouse model by a selective cyclooxygenase-2 inhibitor. Cancer Res 67: 7068-7071.
8. Muller-Decker K, Furstenberger G, Annan N, Kucher D, Pohl-Arnold A, et al. (2006) Preinvasive duct-derived neoplasms in pancreas of keratin 5-promoter cyclooxygenase-2 transgenic mice. Gastroenterology 130: 2165-2178.
9. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, et al. (2006) Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355: 873-884.
10. Rostom A, Dube C, Lewin G, Tsertsvadze A, Barrowman N, et al. (2007) Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 146: 376-389.
11. Van Hecken A, Schwartz JI, Depre M, De Lepeleire I, Dallob A, et al. (2000) Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 40: 1109-1120.
12. Makela A, Kuusi T, Schroder T (1997) Inhibition of serum phospholipase-A2 in acute pancreatitis by pharmacological agents in vitro. Scand J Clin Lab Invest 57: 401-407.
13. Murray B, Carter R, Imrie C, Evans S, O'Suilleabhain C (2003) Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. Gastroenterology 124: 1786-1791.
14. Rodriguez PC, Hernandez CP, Quiceno D, Dubinett SM, Zabaleta J, et al. (2005) Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med 202: 931-939.
15. Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S (2007) Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 67: 4507-4513.
16. Currie GA (1978) Activated macrophages kill tumour cells by releasing arginase. Nature 273: 758-759.
17. Beloussow K, Wang L, Wu J, Ann D, Shen WC (2002) Recombinant arginine deiminase as a potential anti-angiogenic agent. Cancer Lett 183: 155-162.
18. Cheng PN, Lam TL, Lam WM, Tsui SM, Cheng AW, et al. (2007) Pegylated recombinant human arginase (rhArg-peg5,000 mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. Cancer Res 67: 309-317.
19. Lam TL, Wong GK, Chong HC, Cheng PN, Choi SC, et al. (2009) Recombinant human arginase inhibits proliferation of human hepatocellular carcinoma by inducing cell cycle arrest. Cancer Lett.
20. Jung S, Aliberti J, Graemmel P, Sunshine MJ, Kreutzberg GW, et al. (2000) Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol 20: 4106-4114.
21. Nicosia RF, Ottinetti A (1990) Modulation of microvascular growth and morphogenesis by reconstituted basement membrane gel in three-dimensional cultures of rat aorta: a comparative study of angiogenesis in matrigel, collagen, fibrin, and plasma clot. In Vitro Cell Dev Biol 26: 119-128.
22. Corraliza IM, Campo ML, Soler G, Modolell M (1994) Determination of arginase activity in macrophages: a micromethod. J Immunol Methods 174: 231-235.
23. Ben-Sasson SA, Sherman Y, Gavrieli Y (1995) Identification of dying cells-in situ staining. Methods Cell Biol 46: 29-39.
24. Kim KJ, Li B, Winer J, Armanini M, Gillett N, et al. (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841-844.
25. Rodriguez PC, Ochoa AC (2008) Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev 222: 180-191.
26. Jackson PG, Evans SR (2000) Intraperitoneal macrophages and tumor immunity: A review. J Surg Oncol 75: 146-154.
27. Davel LE, Jasnis MA, de la Torre E, Gotoh T, Diament M, et al. (2002) Arginine metabolic pathways involved in the modulation of tumor-induced angiogenesis by macrophages. FEBS Lett 532: 216-220.
28. Chiang CS, Chen FH, Hong JH, Jiang PS, Huang HL, et al. (2008) Functional phenotype of macrophages depends on assay procedures. Int Immunol 20: 215-222.
29. Chang CI, Liao JC, Kuo L (2001) Macrophage arginase promotes tumor cell growth and suppresses nitric oxide-mediated tumor cytotoxicity. Cancer Res 61: 1100-1106.
30. Reymond MA, Schneider C, Hohenberger W, Kockerling F (1998) The pneumoperitoneum and its role in tumor seeding. Dig Surg 15: 105-109.
31. Murthy SM, Goldschmidt RA, Rao LN, Ammirati M, Buchmann T, et al. (1989) The influence of surgical trauma on experimental metastasis. Cancer 64: 2035-2044.
32. Seed MP, Brown JR, Freemantle CN, Papworth JL, Colville-Nash PR, et al. (1997) The inhibition of colon-26 adenocarcinoma development and angiogenesis by topical diclofenac in 2.5% hyaluronan. Cancer Res 57: 1625-1629.
33. Johnsen JI, Lindskog M, Ponthan F, Pettersen I, Elfman L, et al. (2004) Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo. Cancer Res 64: 7210-7215.
34. Davies NM, Anderson KE (1997) Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls. Clin Pharmacokinet 33: 184-213.
35. Lagas JS, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH (2010) Hepatic clearance of reactive glucuronide metabolites of diclofenac in the mouse is dependent on multiple ATP-binding cassette efflux transporters. Mol Pharmacol 77: 687-694.
36. von Rahden BH, Stein HJ, Puhringer F, Koch I, Langer R, et al. (2005) Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinoma. Cancer Res 65: 5038-5044.
37. Hartveit F, Thunold S (1966) Peritoneal fluid volume and the oestrus cycle in mice. Nature 210: 1123-1125.
38. Nachtsheim R, Dudley B, McNeil PL, Howdieshell TR (2006) The peritoneal cavity is a distinct compartment of angiogenic molecular mediators. J Surg Res 134: 28-35.
39. Rudge JS, Holash J, Hylton D, Russell M, Jiang S, et al. (2007) Inaugural Article: VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci U S A 104: 18363-18370.
40. Caso G, McNurlan MA, McMillan ND, Eremin O, Garlick PJ (2004) Tumour cell growth in culture: dependence on arginine. Clin Sci (Lond) 107: 371-379.
41. Gonzalez GG, Byus CV (1991) Effect of dietary arginine restriction upon ornithine and polyamine metabolism during two-stage epidermal carcinogenesis in the mouse. Cancer Res 51: 2932-2939.